As shown by the chart of pharmaceutical company Moderna (MRNA):
→ 2024 was an extremely difficult year, with the price falling by approximately 60%;
→ however, in early 2025, we can see signs of renewed strength.

During yesterday’s session, Moderna’s (MRNA) share price rose by more than 10%, following news of the first death in the US from H5N1 bird flu. According to Barron’s, Moderna is one of the few pharmaceutical companies currently developing a vaccine for H5N1 bird flu, which is spreading rapidly across North America.

This brings back memories of 2020, when MRNA’s share price surged with a significant bullish gap on news of the COVID-19 vaccine trials.

Interestingly, the 2024 low is near the lower boundary of the 2020 gap, around the $37 level. From a technical analysis perspective, this “gap closure” could be viewed as a bullish sign, supported by yesterday’s price action.

Additionally:
→ there has been a breakout above the descending trend channel that dominated the end of 2024;
→ it is possible that price movements may form a new ascending channel (shown in blue);
→ further growth may be hindered by the psychological resistance level of $50.

According to TipRanks, analysts remain cautious about Moderna’s prospects:
→ only 4 out of 19 analysts recommend buying MRNA shares;
→ the average 12-month price target for MRNA is $62.

Buy and sell stocks of the world's biggest publicly-listed companies with CFDs on FXOpen’s trading platform. Open your FXOpen account now or learn more about trading share CFDs with FXOpen.

This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.